Phase 1/2 Study of ZK-Epothilone (ZK-Epo; ZK-219477) in Combination With Carboplatin in Patients With Platinum-sensitive Recurrent Ovarian Cancer.

Trial Profile

Phase 1/2 Study of ZK-Epothilone (ZK-Epo; ZK-219477) in Combination With Carboplatin in Patients With Platinum-sensitive Recurrent Ovarian Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Carboplatin; Sagopilone
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors Bayer HealthCare Pharmaceuticals Inc.; Berlex Inc
  • Most Recent Events

    • 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jan 2009 Planned end date changed from 1 Sep 2009 to 1 Oct 2009 as reported by ClinicalTrials.gov.
    • 12 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top